Anti-interleukin-4 receptor therapy for COPD with dupilumab?
- PMID: 39362745
- DOI: 10.1016/S2213-2600(24)00266-2
Anti-interleukin-4 receptor therapy for COPD with dupilumab?
Conflict of interest statement
JCV has received consultancy fees from AstraZeneca, Chiesi, GSK, MSD/Merck, Regeneron, Sanofi-Aventis, and TEVA; and honoraria for giving lectures for AstraZeneca, Bencard, Chiesi, Genzyme, GSK, Leti, Lupin, MSD/Merck, Mundipharma, Noramed, Regeneron, Sanofi-Aventis, and TEVA.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical